IT-101 is a novel approach to cancer chemotherapy that is currently under investigation in human trials.
The agent represents a nano-particle conjugate that consists of a drug delivery molecule, namely a cyclodextrin-based polymer (CDP) (Cyclosert) and an anti-cancer compound (camptothecin). It was developed by Dr. Mark Davis and associates at Insert Therapeutics (now Calando Pharmaceuticals), hence the IT label. Its novel delivery mode allows the agent and thus the toxic anti-cancer component to be preferentially accumulated in cancer tissue. In turn, toxic side effect are expected to be reduced. The technology was licensed by Calando to Cerulean Pharma in June, 2009.
Rationale
Camptothecin (CPT), an alkaloid extract from plants such as Camptotheca acuminata, exhibits anti-cancer activity possibly due, at least in part, by the inhibition of DNA topoisomerase I resulting in cell death. CPT is linked covalently through a glycine link to CDP which in turn consists of beta-cyclodextrin and polyethylene-glycol (PEG). The compound is water soluble. After intravenous injection, CPT is slowly released as the linkage is hydrolysed. The size of the compound facilitates its extravasation in the more leaky vessels of a cancer and the anticancer drug is retained in the abnormal tissue. As such the chemotherapeutic effect is enhanced in tumor tissue.
Phase I study
The Phase I clinical trial is conducted at the City of Hope Cancer Center. Patients who were entered had refractory and resistant solid tumor cancer of various types (pancreatic cancer, ovarian cancer, non small cell lung cancer). The initial study recruited 36 patients, beginning in May 2006, and is estimated to last until January 2008. Treatment consists of injections on day 1, 8, and 15 followed by 1 week rest.
Animal studies
The agent was studied in mouse xenografts using different cancer models and showed good tolerability and anti-cancer effectiveness in a variety of tumors.
References
- ^ Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, Davis ME. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models. Clin. Cancer Res.2006 Mar 1;12(5):1606-14.
- ^ Cheng J, Khin KT, Davis ME. Antitumor activity of beta-cyclodextrin polymer-camptothecin conjugates. Mol.Pharm. 2004 May-Jun;1(3):183-93.
.
- Phase I study Protocol Study of IT-101 in the Treatment of Advanced Solid Tumors
External links
- Insert Therapeutics website
- Q&
Calando Pharmaceuticals: IT-101
IT-101: CYCLOSERT™-ENHANCED CAMPTOTHECIN . Calando’s lead drug candidate, IT-101, is comprised of Cyclosert™ in combination with the anticancer compound camptothecin for ...
IT-101 Clinical Trial
The Public TV program "Curious" profiled a patient who was being treated with an experimental drug in a clinical trial at City of Hope. You can find out more information about the ...
Encorp Pacific (Canada) - Return-It Electronics
Information for organizations who recycle large quantities of unwanted, end-of-life electronics.
IT 101
IT 101. Yes IT is my major. I believe Network Security is my concentration. Me comming to IT is an interesting story actually. All along I was supposed to be a CIS ...
IT Management-101 (FREE DOWNLOAD)
Get your free copy of IT Management-101. Thousands of copies have been sold; now you can get a copy for free. It provides insight from a CIO of 20 years on what to do, how to go ...
IT 101 Assessment Sample Test
IT 101 Assessment Sample Test: Choose the correct answer for each question by clicking on the appropriate letter.
Information Technology Solutions
The US Micro Commander™ IT-101 is lightweight and small, and easily mounted under a desk or on a wall, the US Micro Commander™ IT-101 offers a clean, new approach to the wired ...
IT 101 Switches Gears
Opinion: It's fall—back-to-school time—and there is no more appropriate time than now to look at IT education and its current crisis.
IT-101 - Wikipedia, the free encyclopedia
IT-101 is a novel approach to cancer chemotherapy that is currently under investigation in human trials. The agent represents a nano-particle conjugate that consists of a drug ...
IT 101
IT 101 Introduction to Interpreting (2) 4 hours lecture per week Prerequisite(s): ENG 100; ASL 202 or equivalent, or instructor consent Comment: This is an 8-week course.